



# register today

Experience our training course offerings in partnership with ITRI  
(台灣生技製藥產程培訓中心 Merck – ITRI 合作計劃)

## Course 1: Introduction to Upstream Processing

**Date: March 13, 2018 (1000-1200)**  
**Speaker: Albert Cheong**

This course provides basic understanding of upstream process in biopharmaceutical industry. The course will review the types of cells used in research and biopharma industries, origin of mammalian cells for cell culture, growth kinetics of mammalian cells, cell culture medium/feeds used for mammalian cell culture and applications in biopharma industry.

**Register now!**

## Course 2: Entry Course to Biopharm

**Date: March 13, 2018 (1300-1500)**  
**Speaker: Seat Yee Lau**

This entry course provides an overview of biopharm manufacturing process. Different unit operations and equipment used in biopharma industry will be reviewed. The course gives a basic understanding on the applications and challenges of clarification, bioreactor, process chemicals, chromatography process, aseptic filters, tangential flow filtration and single use systems

**Register now!**

## Venue Information

- **指導單位:** 經濟部技術處
- **主辦單位:** ITRI · Merck
- **課程地點:** 工業技術研究院 光復院區 1 館 806 會議室 (新竹市光復路 2 段 321 號)
- **線上報名:**  
<https://goo.gl/forms/PIBRq6w3honuAzb12>

### 會議連絡人

- Sonia5014@itri.org.tw (ITRI),  
Tel: 03-5743972
- Dianna .lo@merckgroup.com (Merck),  
Tel: 0905-162-799

## Who should attend?

- Process development scientist with less than 1 year experience
- Engineers and technicians with less than 1 year experience
- University students who are interested to join biopharma industry
- Executives working in biopharma firms with non-bio background
- Employees who are looking for switch of career

**Launch Promotion FREE!**

★ **首發免費 · 歡迎踴躍報名**



## SPEAKER PROFILE



### **Albert Cheong**

MSAT Manager/Lead Scientist

Manufacturing, Sciences and Technology - Upstream Cell Culture Media and Media Development Services

Mr Albert Cheong comes with 13 years of life sciences experience, working in academic research laboratories as well as in the biopharmaceutical industry. He has worked with S\*BIO Pte Ltd developing cell-based assays and assessing in-house synthesised small molecule inhibitors (JAK2i, HDACi, mTORi) as drug combination treatments using a panel of cancer cell lines. Prior to joining SAFC, Sigma-Aldrich Pte Ltd (a subsidiary of Merck KGaA), he was a Senior Scientist at Lonza Biologics Singapore, leading a small team on cell line development, process development (STRs, ALRs, waves) and pre-clinical material supply projects for APAC customers.

---



### **Seat Yee Lau**

Senior Technology Manager

Seat Yee is Senior Technology Manager at Merck Taiwan, delivering technical product expertise and market initiative to Taiwan's biopharmaceutical industry. Seat Yee has over 10 years of experience in Biopharmaceutical industry for downstream product applications, which includes clarification, tangential flow filtration, sterile, virus and single use systems. Experienced in process implementation, troubleshooting as well as small scale process optimization, she had also provided downstream processing technical expertise to multiple clients in South East Asia. Prior to joining Merck Taiwan, Seat Yee worked at Samsung Biologics in South Korea for the last 2.5 years on technology transfer projects focusing on gap analysis, FMEA, process validation plan, change control, deviations investigations and facility inspection activities